Carlumab

From WikiMD's Wellness Encyclopedia

Carlumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number 915404-94-3
PubChem
DrugBank
ChemSpider none
KEGG D09877


Carlumab (alternate identifier CNTO 888[1]) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa)[2] that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1).[3][4][5] Carlumab was under development for use in the treatment of oncology and immune indications[6][7] and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes.[2]

The inhibitory binding of Carlumab to CCL2 was hypothesized to inhibit angiogenesis and consequently modulate tumor cell proliferation.[3][2] Studies focusing on the effects of Carlumab have been performed in vitro on cell lines and in vivo on mice and in humans including phase 1 and phase 2 clinical trials evaluating the efficacy, safety and dose requirements of the drug. Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis,[8][9] castration-resistant metastatic prostate cancer[1][10] and solid tumors.[11][12]

Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012[13] due to limited success in clinical trials.

References[edit | edit source]

  1. ↑ 1.0 1.1 Pienta, Kenneth J., Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer, Investigational New Drugs, Vol. 31(Issue: 3), pp. 760–768, DOI: 10.1007/s10637-012-9869-8, PMID: 22907596,
  2. ↑ 2.0 2.1 2.2 Janssen 2014 Compound Information CNT0888 Full text, ,
  3. ↑ 3.0 3.1 NCI Drug Dictionary Full text, National Cancer Institute, 2011-02-02, Accessed on: 2017-03-24.
  4. ↑ Fetterly, Gerald J., Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data, The Journal of Clinical Pharmacology, Vol. 53(Issue: 10), pp. 1020–1027, DOI: 10.1002/jcph.140, PMID: 23878055,
  5. ↑ Obmolova, Galina, Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888, Molecular Immunology, Vol. 51(Issue: 2), pp. 227–233, DOI: 10.1016/j.molimm.2012.03.022, PMID: 22487721,
  6. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab Full text, , American Medical Association,
  7. ↑ World Health Organization, Proposed International Nonproprietary Names: List 104 Full text, , World Health Organization, 2010, Geneva, Accessed on: 17 August 2015.
  8. ↑ , www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A3376, American Thoracic Society, Series: American Thoracic Society International Conference Abstracts, DOI: 10.1164/ajrccm-conference.2013.187.1_meetingabstracts.a3376, Pages: A3376,
  9. ↑ A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Full Text View - ClinicalTrials.gov Full text, clinicaltrials.gov, Accessed on: 2017-03-24.
  10. ↑ A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov Full text, clinicaltrials.gov, Accessed on: 2017-03-24.
  11. ↑ Sandhu, Shahneen K., A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors, Cancer Chemotherapy and Pharmacology, Vol. 71(Issue: 4), pp. 1041–1050, DOI: 10.1007/s00280-013-2099-8, PMID: 23385782,
  12. ↑ First Study of the Safety of CNTO 888 in Patients With Solid Tumors - Full Text View - ClinicalTrials.gov Full text, clinicaltrials.gov, Accessed on: 2017-03-24.
  13. ↑ Research and Development | MorphoSys 2012 Full text, reports.morphosys.com, Accessed on: 2017-03-24.




Inmunoglobulina.png
   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
Carlumab Resources
Wikipedia
Medicine-stub.png
This article is a stub related to medicine. You can help WikiMD by expanding it!
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.com/w/index.php?title=Carlumab&oldid=5192478"

Contributors: Prab R. Tumpati, MD